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1. INTRODUCTION {#mgg3738-sec-0005}
===============

Rheumatoid arthritis (RA) is a chronic, systemic, and autoimmune disease that occurs at any age. The clinical presentation of RA is characterized by inflammation of the joint synovium, progressive articular destruction, and other comorbidities such as cardiovascular disease, lung disease, infections, and some malignancies (Metsios, Stavropoulos‐Kalinoglou, & Kitas, [2015](#mgg3738-bib-0021){ref-type="ref"}), which usually contribute to declining life expectancy, early unemployment, and severe disability even death (Sokka et al., [2009](#mgg3738-bib-0027){ref-type="ref"}). The prevalence is about three times higher in women than that in men (Derksen, Huizinga, & van der Woude, [2017](#mgg3738-bib-0008){ref-type="ref"}). Clinically, there represents a huge challenge for immediate recognition in early stage of RA. And the prognosis is poor due to the lack of early identification and early treatment of the disease.

Several studies have demonstrated that RA is a complicated disease resulted from genetic factors, environmental factors, and their interactions (Chatzikyriakidou, Voulgari, Lambropoulos, & Drosos, [2013](#mgg3738-bib-0005){ref-type="ref"}), in which genetic factors have been estimated to account for about 60% to RA susceptibility (Kurko et al., [2013](#mgg3738-bib-0017){ref-type="ref"}; McInnes & Schett, [2011](#mgg3738-bib-0020){ref-type="ref"}). Cytokines were reported to contribute to the induction and maintenance of inflammation and play a key role in the pathogenesis of immunological diseases (Noack & Miossec, [2017](#mgg3738-bib-0022){ref-type="ref"}). Furthermore, numerous studies showed that immune cytokine genes play a decisive role in RA pathogenesis such as *IL‐4*, *IL‐6*, *IL‐22* (Jeon, Kim, Kim, & Suh, [2013](#mgg3738-bib-0013){ref-type="ref"}; Krabben et al., [2013](#mgg3738-bib-0015){ref-type="ref"}; Roeleveld & Koenders, [2015](#mgg3738-bib-0024){ref-type="ref"}).

The interleukin‐7 receptor (*IL7R*; OMIM: 146661) encodes a receptor protein that plays an important role in the development of immune cells (Galarza‐Munoz et al., [2017](#mgg3738-bib-0010){ref-type="ref"}). Previous studies have confirmed that the *IL‐7R* gene may be associated with a variety of autoimmune diseases, mainly including multiple sclerosis, Type 1 diabetes (T1D), and so on (Galarza‐Munoz et al., [2017](#mgg3738-bib-0010){ref-type="ref"}; Santiago et al., [2008](#mgg3738-bib-0026){ref-type="ref"}; Todd et al., [2007](#mgg3738-bib-0029){ref-type="ref"}). While studies on the association between *IL‐7R* gene polymorphisms and RA have rarely been reported so far, especially in the Han Chinese population.

This study was to explore the relationship between *IL‐7R* gene polymorphisms and susceptibility to RA. We designed a case--control study including 507 RA patients and 499 healthy controls for association analysis and further tried to find new *IL‐7R* susceptibility loci for RA among the Han Chinese population. Finally, we hope that we can further clarify their relationship with RA risk among the Han Chinese population.

2. MATERIALS AND METHODS {#mgg3738-sec-0006}
========================

2.1. Ethics compliance {#mgg3738-sec-0007}
----------------------

This case--control study was conducted in accordance with the ethical standards of the Declaration of Helsinki and following international guidelines. The study protocol was approved by the ethics committee of the Affiliated Hospital of Xizang Minzu University. Informed consents were obtained from all participants. The experimental protocol was implemented in accordance with the approved guidelines.

2.2. Subjects {#mgg3738-sec-0008}
-------------

The Han Chinese population‐based case--control study containing 507 RA patients diagnosed from September 2015 to February 2018 from the Affiliated Hospital of Xizang Minzu University was conducted. In the meantime, we undertook rigorous screening for RA patients based on American College of Rheumatology 1987 classification criteria (Arnett et al., [1988](#mgg3738-bib-0001){ref-type="ref"}). RA patients were diagnosed by routine biochemical blood analysis (including C‐reaction protein \[CRP\], rheumatoid factor, erythrocyte sedimentation rate \[ESR\], anti‐cyclic citrulline antibody \[CCP\]) and X‐rays of small joints. Patients with other autoimmune and tumor diseases were excluded from the study. At the same time, the 499 healthy controls were randomly selected from the Affiliated Hospital of Xizang Minzu University and were diagnosed without immune disease or other diseases. All subjects were unrelated individuals and at least three generations of Han ancestors.

2.3. Sample collection {#mgg3738-sec-0009}
----------------------

Peripheral venous blood samples were collected from each participants in an anti‐coagulation tube and stored at −80°C freezer for DNA extraction. According to the manufacturer\'s instructions to the GoldMag‐Mini Purification Kit (GoldMag Co.Ltd. Xi\'an city, China), we isolated genomic DNA from whole blood samples. And the concentration and purity of the DNA were measured using the NanoDrop 2000 (Thermo Fisher Scientific, Waltham, Massachusetts, USA) to ensure accurate and uniform concentration.

2.4. Single nucleotide polymorphisms selection and genotyping {#mgg3738-sec-0010}
-------------------------------------------------------------

A total of five single nucleotide polymorphisms (SNPs) (rs10213865, rs969129, rs118137916, rs10053847, rs6451231) in *IL‐7R* (NG_009567.1) were selected with a minor allele frequency \>0.05 in the 1000 Genomes Project (<http://www.internationalgenome.org/>) for further genotyping. The primers for amplification and extension reactions were designed with Agena MassARRAY Assay Design 3.0 Software (Data [S1](#mgg3738-sup-0001){ref-type="supplementary-material"}) (Gabriel, Ziaugra, & Tabbaa, [2009](#mgg3738-bib-0009){ref-type="ref"}). Agena MassARRAY RS1000 was used to perform the SNP genotyping according to the manufacturer\'s instruction, and we used Agena Typer 4.0 software for data management and analysis (Gabriel et al., [2009](#mgg3738-bib-0009){ref-type="ref"}; Thomas et al., [2007](#mgg3738-bib-0028){ref-type="ref"}).

2.5. Statistical analysis {#mgg3738-sec-0011}
-------------------------

The SPSS 19.0 (SPSS, Chicago, IL, USA) and Microsoft Excel were used to perform statistical analyses. The gender distribution between the cases and the controls was compared by two‐sided Chi‐square tests, and the age distribution was evaluated by Student\'s *t* tests. The genotype frequencies of the control group were tested for departure from the Hardy--Weinberg equilibrium (HWE) using Chi‐square test. We calculated the allele frequencies of the cases and controls with Chi‐squared test. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the association between *IL‐7R* gene polymorphisms and the RA risk using logistic regression analysis with adjustment for age and gender (Bland & Altman, [2000](#mgg3738-bib-0003){ref-type="ref"}). The multiple genetic models analyses were applied using PLINK software (Version 1.07) to evaluate the associations between SNPs and the RA risk (Clarke et al., [2011](#mgg3738-bib-0006){ref-type="ref"}). Then, we conducted stratification analysis on age and gender. Finally, we performed linkage disequilibrium (LD) and haplotype analysis using the Haploview software package (version 4.2). All *p* values of statistical tests in this study were two‐sided, and *p* \< 0.05 indicated statistical significance.

3. RESULTS {#mgg3738-sec-0012}
==========

3.1. Characteristics of study population {#mgg3738-sec-0013}
----------------------------------------

A total of 507 patients (135 males and 372 females) with RA and 499 healthy individuals (135 males and 364 females) were enrolled for this study. Their demographic and clinical data were described in Table [1](#mgg3738-tbl-0001){ref-type="table"}. The age at diagnosis of the two groups were 54.34 ± 12.03 years in the case group and 53.89 ± 9.56 years in the control group. No significant difference was found in the distribution differences of age and gender between RA patients and healthy controls. The proportion of male and female in the case group and control group was the same (27% and 73%, respectively). In addition, we analyzed the clinical indicators in the case group. The Mean ± *SD* of CRP and ESR among 507 cases were 30.88 ± 40.25 mg/L and 44.14 ± 30.73 mm/hr, respectively. The Mean ± *SD* of RF among 497 cases were 165.10 ± 147.36 KIU/L. In addition, the Mean ± *SD* of CCP among 260 cases were 75.18 ± 60.95 RU/ml.

###### 

Basic characteristics of the RA patients and the controls

  Variable              Cases (*n* = 507)   Controls (*n* = 499)   *p*‐Value                                                    
  --------------------- ------------------- ---------------------- --------------------------------------------- -------------- ---------------------------------------------
  Gender                                                           0.879[a](#mgg3738-note-0004){ref-type="fn"}                  
  Male                  135 (27%)                                  135 (27%)                                                    
  Female                372 (73%)                                  364 (73%)                                                    
  Age, year                                 54.34 ± 12.03                                                        53.89 ± 9.56   0.508[b](#mgg3738-note-0005){ref-type="fn"}
  ≥54                   261 (51%)                                  221 (44%)                                                    
  \<54                  246 (49%)                                  278 (56%)                                                    
  Clinical parameters                                                                                                           
  CRP (mg/L)            507 (100%)          30.88 ± 40.25                                                                       
  RF (KIU/L)            497 (98.30%)        165.10 ± 147.36                                                                     
  ESR (mm/hr）          507 (100%)          44.14 ± 30.73                                                                       
  CCP ( RU/ml)          260 (51.30%)        75.18 ± 60.95                                                                       

*p* \< 0.05 indicates statistical significance.

Abbreviations: CCP, Anti‐cyclic citrullinated peptide; CRP, C‐reaction protein; ESR, Erythrocyte sedimentation rate; RA, Rheumatoid arthritis; RF, Rheumatoid factor; *SD*, Standard deviation.

*p* value was calculated from two‐sided Chi‐squared tests.

*p* value was calculated from Student\'s *t* test.
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3.2. The association analysis between IL7R SNPs and RA susceptibility {#mgg3738-sec-0014}
---------------------------------------------------------------------

The basic information on the five SNPs examined in this study was summarized in Table [2](#mgg3738-tbl-0002){ref-type="table"}. Those SNPs were in accordance with HWE in the controls (*p* \> 0.05). The two‐sided Chi‐squared test was used to compare the differences in frequency distributions of alleles between RA cases and controls. The frequency of the minor allele "G" of rs969129 was significantly higher in RA cases than that in controls (48.0% vs. 42.5%), which suggested that "G" allele of rs969129 was a non‐protective allele against risk of RA (OR = 1.25, 95% CI: 1.05--1.49, *p* = 0.013). Similarly, we found the frequency of the minor allele "C" of rs6451231 was significantly higher in RA case group than that in control group (41.0% vs. 36.1%). And it was a risk factor for RA (OR = 1.23, 95% CI: 1.03--1.48, *p* = 0.023). In a word, rs969129 and rs6451231 were associated with an increased risk of RA in allele model.

###### 

Basic information of selected SNPs in this study

  SNP           Gene     Chr   position   Alleles A/B   MAF     *p^a^*‐HWE   OR (95% CI)   *p* [a](#mgg3738-note-0007){ref-type="fn"}   
  ------------- -------- ----- ---------- ------------- ------- ------------ ------------- -------------------------------------------- --------------------------------------------------
  rs10213865    *IL7R*   5     35857748   A/C           0.195   0.167        0.199         1.21 (0.96--1.52)                            0.104
  rs969129      *IL7R*   5     35861166   G/T           0.480   0.425        0.647         1.25 (1.05--1.49)                            **0.013** [b](#mgg3738-note-0008){ref-type="fn"}
  rs118137916   *IL7R*   5     35863436   A/G           0.074   0.090        0.786         0.81 (0.59--1.11)                            0.185
  rs10053847    *IL7R*   5     35878038   A/G           0.154   0.153        0.864         1.00 (0.79--1.28)                            0.973
  rs6451231     *IL7R*   5     35878825   C/T           0.410   0.361        0.628         1.23 (1.03--1.48)                            **0.023** [b](#mgg3738-note-0008){ref-type="fn"}

Abbreviations: Alleles A/B, Minor/major alleles; CI, Confidence interval; HWE, Hardy--Weinberg equilibrium; MAF, Minor allele frequency; OR, Odds ration; SNP, Single‐nucleotide polymorphism.

*p* values were calculated using two‐sided Chi‐squared test (the major allele of each SNP was a reference allele).

Bold values represents a positive result.

*p* \< 0.05 indicates statistical significance.
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Next, we hypothesized that the minor allele of each SNP was a risk factor and analyzed the associations between each variant and RA risk under four genetic models by unconditional logistic regression analysis with adjustments for age and gender. As shown in Table [3](#mgg3738-tbl-0003){ref-type="table"}, our analyses showed that rs969129 in *IL7R* gene was associated with a 1.34‐fold increase the risk of RA in the co‐dominant model (adjusted, OR = 1.59; 95% CI: 1.11--2.28; *p* = 0.012 for the 'G/G' genotype), 1.34‐fold increase the risk of RA in the dominant model (adjusted, OR = 1.34, 95% CI = 1.02--1.76, *p* = 0.037 for the 'G/T‐G/G' genotype), 1.38‐fold increase the risk of RA in the recessive model (adjusted, OR = 1.38, 95% CI = 1.01--1.89, *p* = 0.043 for the 'G/G' genotype), and 1.26‐fold increase the risk of RA in the log‐additive model (adjusted, OR = 1.26, 95% CI = 1.05--1.51, *p* = 0.011), respectively. The rs6451231 in *IL7R* gene was associated with a 1.55‐fold increase the risk of RA in the co‐dominant model (adjusted, OR = 1.55, 95% CI = 1.05--2.29, *p* = 0.026 for the 'C/C' genotype), and 1.24‐fold increase the risk of RA in the log‐additive model (adjusted OR = 1.24, 95% CI = 1.03--1.49, *p* = 0.021), respectively.

###### 

Relationships between *IL7R* polymorphisms and RA risk

  SNP            Model        Genotype      Case          Control                 Before adjusted                                    After adjusted                                                                                        
  -------------- ------------ ------------- ------------- ----------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- --------------------------------------------------
  rs969129       Codominant   T/T           134 (26.4%)   162 (32.5%)             1                                                  **0.012** [c](#mgg3738-note-0012){ref-type="fn"}   1                                                  **0.012** [c](#mgg3738-note-0012){ref-type="fn"}
                 G/T          259 (51.1%)   250 (50.1%)   **1.25 (0.94--1.67)**                                                      1.25 (0.94--1.67)                                                                                     
                 G/G          114 (22.5%)   87 (17.4%)    **1.58 (1.10--2.27)**                                                      **1.59 (1.11--2.28)**                                                                                 
  Dominant       T/T          134 (26.4%)   162 (32.5%)   1                       **0.036** [c](#mgg3738-note-0012){ref-type="fn"}   1                                                  **0.037** [c](#mgg3738-note-0012){ref-type="fn"}   
                 G/T‐G/G      373 (73.6%)   337 (67.5%)   **1.34 (1.02--1.76)**                                                      **1.34 (1.02--1.76)**                                                                                 
  Recessive      T/T‐G/T      393 (73.6%)   412 (82.6%)   1                       **0.046** [c](#mgg3738-note-0012){ref-type="fn"}   1                                                  **0.043** [c](#mgg3738-note-0012){ref-type="fn"}   
                 G/G          114 (26.4%)   87 (17.4%)    **1.37 (1.01--1.88)**                                                      **1.38 (1.01--1.89)**                                                                                 
  Log‐additive   ---          ---           ---           **1.26 (1.05--1.50)**   **0.012** [c](#mgg3738-note-0012){ref-type="fn"}   **1.26 (1.05--1.51)**                              **0.011** [c](#mgg3738-note-0012){ref-type="fn"}   
  rs6451231      Codominant   T/T           174 (34.4%)   201 (40.3%)             1                                                  **0.027** [c](#mgg3738-note-0012){ref-type="fn"}   1                                                  **0.026** [c](#mgg3738-note-0012){ref-type="fn"}
                 C/T          249 (49.2%)   236 (47.3%)   1.22 (0.93--1.60)                                                          1.22 (0.93--1.60)                                                                                     
                 C/C          83 (16.4%)    62 (12.4%)    **1.55 (1.05--2.28)**                                                      **1.55 (1.05--2.29)**                                                                                 
  Dominant       T/T          174 (34.4%)   201 (40.3%)   1                       0.054                                              1                                                  0.052                                              
                 C/T‐C/C      332 (65.6%)   298 (59.7%)   1.29 (0.10--1.66)                                                          1.29 (1.00--1.67)                                                                                     
  Recessive      T/T‐C/T      423 (83.6%)   437 (87.6%)   1                       0.074                                              1                                                  0.071                                              
                 C/C          83 (16.4%)    62 (12.4%)    1.38 (0.97--1.97)                                                          1.39 (0.97--1.98)                                                                                     
  Log‐additive   ---          ---           ---           **1.24 (1.03--1.49)**   **0.022** [c](#mgg3738-note-0012){ref-type="fn"}   **1.24 (1.03--1.49)**                              **0.021** [c](#mgg3738-note-0012){ref-type="fn"}   

Abbreviations: CI, Confidence interval; OR, Odds ration; SNP, Single‐nucleotide polymorphism.

*p*‐Values were calculated from logistic regression analysis.

*p*‐Values were calculated by logistic regression analysis with adjustments for age and gender.

*p* \< 0.05 indicates statistical significance.

Bold values represents a positive result.
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Then, we analyzed the association between selected SNPs and RA risk with stratified age and gender in Table [4](#mgg3738-tbl-0004){ref-type="table"}. After the stratification analysis by age adjusted by age and gender, there was no significant differences between selected SNPs and risk of RA in patients who were over 54 years old. However, in patients who were under the age of 54 years, the rs969129 (*IL7R*) was associated with an increased risk of RA in the dominant model (OR = 1.54, 95% CI = 1.05--2.27, *p* = 0.029), log‐additive model (OR = 1.31, 95% CI = 1.02--1.69, *p* = 0.036). The rs6451231 (*IL7R*) was associated with the elevated risk of RA in the co‐dominant model (OR = 1.48, 95% CI = 1.01--2.18, *p* = 0.044), dominant model (OR = 1.51, 95% CI = 1.05--2.18, *p* = 0.027), log‐additive model (OR = 1.32, 95% CI = 1.02--1.72, *p* = 0.038). After the stratification analysis of gender adjusted by age, we observed that rs6451231 was significantly associated with an increased risk of RA in males under the dominant model (OR = 1.67, 95% CI = 1.01--2.75, *p* = 0.046), log‐additive model (OR = 1.47, 95% CI = 1.01--2.14, *p* = 0.042). Rs969129 was found to be associated with an increased risk of RA in females under log‐additive model (OR = 1.25, 95% CI = 1.01--1.53, *p* = 0.036).

###### 

Stratified analysis on associations between selected SNPs and RA risk

  SNP            Model     Genotype            ≥54     \<54                    Male                                                Female                                                                                                                                                  
  -------------- --------- ------------------- ------- ----------------------- --------------------------------------------------- ----------------------- --------------------------------------------------- ----------------------- --------------------------------------------------- ---------------------------------------------------
  rs969129       Allele    T                   1       0.146                   1                                                   **0.042^\*^**           1                                                   0.166                   1                                                   **0.038** [\*](#mgg3738-note-0014){ref-type="fn"}
                 G         1.21 (0.94--1.56)           **1.29 (1.01--1.65)**                                                       1.27 (0.91--1.79)                                                           **1.24 (1.01--1.53)**                                                       
  Codominant     T/T       1                   0.185   1                       0.083                                               1                       0.275                                               1                       0.033                                               
                 G/T       1.15 (0.75--1.75)           1.49 (0.99--2.25)                                                           1.52 (0.87--2.65)                                                           1.17 (0.83--1.63)                                                           
                 G/G       1.64 (0.96--2.79            1.67 (1.00--2.78)                                                           1.62 (0.78--3.38)                                                           1.57 (1.04--2.38)                                                           
  Dominant       T/T       1                   0.252   1                       **0.029** [\*](#mgg3738-note-0014){ref-type="fn"}   1                       0.111                                               1                       0.134                                               
                 G/T‐G/G   1.26 (0.85--1.89)           **1.54 (1.05--2.27)**                                                       1.54 (0.91--2.63)                                                           1.27 (0.93--1.75)                                                           
  Recessive      T/T‐G/T   1                   0.085   1                       0.246                                               1                       0.511                                               1                       0.051                                               
                 G/G       1.50 (0.95--2.37)           1.30 (0.84--2.02)                                                           1.24 (0.65--2.34)                                                           1.43 (1.00--2.04)                                                           
  Log‐additive   ‐         1.26 (0.97--1.65)   0.081   **1.31 (1.02--1.69)**   **0.036** [\*](#mgg3738-note-0014){ref-type="fn"}   1.31 (0.91--1.87)       0.147                                               **1.25 (1.01--1.53)**   **0.036** [\*](#mgg3738-note-0014){ref-type="fn"}   
  rs6451231      Allele    T                   1       0.236                   1                                                   0.046                   1                                                   0.05                    1                                                   0.14
                 C         1.17 (0.90--1.52)           1.29 (1.00--1.66)                                                           1.42 (1.00--2.01)                                                           1.17 (0.95--1.44)                                                           
  Codominant     T/T       1                   0.22    1                       **0.044** [\*](#mgg3738-note-0014){ref-type="fn"}   1                       0.115                                               1                       0.285                                               
                 C/T       1.09 (0.73--1.61)           **1.48 (1.01--2.18)**                                                       1.60 (0.95--2.69)                                                           1.11 (0.81--1.52)                                                           
                 C/C       1.64 (0.93--2.88)           1.61 (0.92--2.81)                                                           2.02 (0.90--4.53)                                                           1.43 (0.92--2.22)                                                           
  Dominant       T/T       1                   0.35    1                       **0.027** [\*](#mgg3738-note-0014){ref-type="fn"}   1                       **0.046** [\*](#mgg3738-note-0014){ref-type="fn"}   1                                                                           
                 C/T‐C/C   1.20 (0.82--1.74)           **1.51 (1.05--2.18)**                                                       **1.67 (1.01--2.75)**                                                       1.18 (0.87--1.59)       0.279                                               
  Recessive      T/T‐C/T   1                   0.091   1                       0.338                                               1                       0.261                                               1                                                                           
                 C/C       1.56 (0.93--2.62)           1.28 (0.77--2.14)                                                           1.54 (0.73--3.26)                                                                                                                                       
  Log‐additive   ---       1.23 (0.94--1.61)   0.124   **1.32 (1.02--1.72)**   **0.038** [\*](#mgg3738-note-0014){ref-type="fn"}   **1.47 (1.01--2.14)**   **0.042** [\*](#mgg3738-note-0014){ref-type="fn"}   1.18 (0.95--1.45)       0.130                                               

Abbreviations: CI, Confidence interval; OR, Odds ration; SNP, Single‐nucleotide polymorphism.

Bold values represents a positive result.

*p* \< 0.05 indicates statistical significance.
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Furthermore, we analyzed the relationship between genotypes at different loci and clinical parameters, as displayed in Table [5](#mgg3738-tbl-0005){ref-type="table"}. Our results demonstrated that RA patients with different genotype of rs10213865 had significantly different CCP level (*p* = 0.011). Similarly, the genotypes of rs10053847 in the RA patients showed significantly different CRP and ESR level (*p* = 0.027, *p* = 0.017, respectively).

###### 

The relationship between genotypes at different loci and clinical parameters

  SNP‐ID        Variable          Genotype          Mean ± standard deviation                           *p*‐Value
  ------------- ----------------- ----------------- --------------------------------------------------- ----------------------------------------------
  rs10213865    CRP               AA                38.48 ± 38.48                                       0.164
  CA            43.85 ± 43.85                                                                           
  CC            37.41 ± 37.41                                                                           
  RF            AA                161.91 ± 150.89   0.487                                               
  CA            175.07 ± 144.50                                                                         
  CC            139.86 ± 106.11                                                                         
  ESR           AA                43.31 ± 31.51     0.601                                               
  CA            46.15 ± 29.91                                                                           
  CC            41.95 ± 23.76                                                                           
  CCP           AA                82.20 ± 62.72     **0.011** [\*](#mgg3738-note-0016){ref-type="fn"}   
  CA            62.90 ± 55.87                                                                           
  CC            28.83 ± 7.00                                                                            
  rs969129      CRP               TT                28.67 ± 35.15                                       0.716
  GT            32.15 ± 45.07                                                                           
  GG            30.58 ± 33.98                                                                           
  RF            TT                151.49 ± 131.73   0.473                                               
  GT            170.02 ± 157.01                                                                         
  GG            169.70 ± 142.13                                                                         
  ESR           TT                45.15 ± 33.23     0.837                                               
  GT            44.20 ± 30.03                                                                           
  GG            42.82 ± 29.43                                                                           
  CCP           TT                87.56 ± 66.16     0.052                                               
  GT            67.25 ± 55.21                                                                           
  GG            82.98 ± 67.58                                                                           
  rs118137916   CRP               AA                30.64 ± 40.19                                       0.939
  GA            32.56 ± 42.28                                                                           
  GG            30.93 ± 25.08                                                                           
  RF            AA                161.26 ± 144.19   0.248                                               
  GA            194.58 ± 167.80                                                                         
  GG            146.12 ± 147.41                                                                         
  ESR           AA                43.74 ± 30.38     0.168                                               
  GA            44.73 ± 32.17                                                                           
  GG            67.50 ± 37.30                                                                           
  CCP           AA                72.64 ± 60.60     0.173                                               
  GA            94.14 ± 62.14                                                                           
  GG            109.00 ± 0.00                                                                           
  rs10053847    CRP               AA                0.22 ± 0.16                                         0.027[\*](#mgg3738-note-0016){ref-type="fn"}
  GA            36.99 ± 42.99                                                                           
  GG            28.80 ± 39.01                                                                           
  RF            AA                82.26 ± 32.09     0.165                                               
  GA            180.59 ± 151.16                                                                         
  GG            159.89 ± 146.24                                                                         
  ESR           AA                47.85 ± 30.95     0.017[\*](#mgg3738-note-0016){ref-type="fn"}        
  GA            43.07 ± 30.54                                                                           
  GG            44.14 ± 30.73                                                                           
  CCP           AA                74.28 ± 56.95     0.453                                               
  GA            74.63 ± 61.98                                                                           
  GG            75.18 ± 60.95                                                                           
  rs6451231     CRP               TT                31.54 ± 41.11                                       0.847
  TC            31.28 ± 41.97                                                                           
  CC            28.61 ± 33.03                                                                           
  RF            TT                152.57 ± 134.05   0.356                                               
  TC            168.53 ± 155.00                                                                         
  CC            179.01 ± 16.56                                                                          
  ESR           TT                45.75 ± 33.48     0.501                                               
  TC            44.16 ± 29.33                                                                           
  CC            40.92 ± 28.96                                                                           
  CCP           TT                82.86 ± 65.73     0.119                                               
  TC            67.60 ± 54.82                                                                           
  CC            84.10 ± 68.79                                                                           

Abbreviations: CCP, Anti‐cyclic citrullinated peptide; CRP, C‐reaction protein; ESR, Erythrocyte sedimentation rate; RF, Rheumatoid factor; *SD*, Standard deviation.

Bold values represents a positive result.

*p* \< 0.05 indicates statistical significance.

John Wiley & Sons, Ltd

3.3. Haplotype association {#mgg3738-sec-0015}
--------------------------

Finally, we used allele frequency data from all subjects to perform the LD block (Figure [1](#mgg3738-fig-0001){ref-type="fig"}). LD block in *IL7R* gene on chromosome 5 was constructed by rs969129, rs118137916, rs10053847, rs6451231 and there was a significant linkage. The association analysis results between haplotypes and RA risk were shown in Table [6](#mgg3738-tbl-0006){ref-type="table"}. The haplotype "GAGC" was associated with an increased risk of RA after the adjustment (OR = 1.35; 95% CI = 1.09--1.67; *p* = 0.006).

![Linkage disequilibrium (LD) plots containing five SNPs from *IL7R*](MGG3-7-e00738-g001){#mgg3738-fig-0001}

###### 

The haplotype of four SNPs in *IL7R* and the RA risk

  SNP‐ID      rs969129   rs118137916   rs10053847   rs6451231   Haplotype   Frequency   OR (95% CI)         *p*                                                 
  ----------- ---------- ------------- ------------ ----------- ----------- ----------- ------------------- --------------------------------------------------- -------
  Haplotype   G          A             A            C           GAAC        0.846       0.847               1.00 (0.78--1.28)                                   0.985
  G           A          G             C            GAGC        0.256       0.206       1.35 (1.09--1.67)   **0.006** [\*](#mgg3738-note-0019){ref-type="fn"}   
  T           G          G             T            TGGT        0.926       0.910       1.23 (0.90--1.69)   0.198                                               
  G           A          G             T            GAGT        0.930       0.935       0.92 (0.65--1.31)   0.665                                               
  T           A          G             T            TAGT        0.554       0.516       1.17 (0.98--1.40)   0.077                                               

*p* values were calculated by Wald test adjusted by gender and age.

Abbreviations: CI, Confidence interval; OR, Odds ration; SNP, Single‐nucleotide polymorphism.

Bold values represents a positive result.

*p* \< 0.05 indicates statistical significance.

John Wiley & Sons, Ltd

4. DISCUSSION {#mgg3738-sec-0016}
=============

Rheumatoid arthritis is a multifactorial disease caused by environmental and genetic factors and their interactions. In this hospital‐based case--control study, we evaluated the association between the five selected SNPs (rs10213865, rs969129, rs118137916, rs10053847, and rs6451231) in *IL‐7R* gene and the risk of RA in the Han Chinese population. We found rs969129 and rs6451231 in this gene were significantly associated with an increased risk of RA. And there was a strong LD between the four SNPs (rs969129, rs118137916, rs10053847, and rs6451231). Those results indicated the *IL‐7R* gene may be a risky gene for RA in the Han Chinese population.

*IL‐7* receptor is made up of a heterodimer consisting of two subunits, the *IL‐7R* α chain and the γc chain. It is involved in the regulation of *IL‐7* signaling pathway (Rose et al., [2010](#mgg3738-bib-0025){ref-type="ref"}), which plays an important role in the growth, reproduction and differentiation of immature thymus cells, and acts as an irreplaceable decisive role in maintaining the balance of T cells in human peripheral blood (Hong, Luckey, & Park, [2012](#mgg3738-bib-0012){ref-type="ref"}; Jiang et al., [2007](#mgg3738-bib-0014){ref-type="ref"}; Walsh, [2010](#mgg3738-bib-0031){ref-type="ref"}). According to the binding state of *IL‐7R*, *IL‐7R* can be divided into membrane‐bound receptor (*mIL‐7R*) and soluble receptor (*sIL‐7R*). The latter can enhance the biological activity of *IL‐7* and promote the proliferation of self‐reactive T cells, which may be correlated with the autoimmune diseases (Boyman, Ramsey, Kim, Sprent, & Surh, [2008](#mgg3738-bib-0004){ref-type="ref"}; Corfe & Paige, [2012](#mgg3738-bib-0007){ref-type="ref"}; Lundstrom et al., [2013](#mgg3738-bib-0019){ref-type="ref"}), including RA (van Roon et al., [2005](#mgg3738-bib-0030){ref-type="ref"}), T1D (Harrison, [2012](#mgg3738-bib-0011){ref-type="ref"}) and systemic lupus erythematosus (Badot et al., [2013](#mgg3738-bib-0002){ref-type="ref"}) etc. In a published article about T1D, *IL‐7Rα* monoclonal antibody can prevent the occurrence of diabetes, and can also alleviate the new occurrence of nonobese diabetic mice model, which showed that *IL‐7R* may be involved in the pathogenesis of T1D (Penaranda et al., [2012](#mgg3738-bib-0023){ref-type="ref"}). Studies have shown that the nonsynonymous rs6897932 in *IL‐7R* gene may affect the subtype, expression, and function of *IL‐7R* (Kreft et al., [2012](#mgg3738-bib-0016){ref-type="ref"}; Lundstrom, Fewkes, & Mackall, [2012](#mgg3738-bib-0018){ref-type="ref"}). Therefore, the variants in *IL‐7R* gene may be associated with the occurrence and development of other immune diseases. However, studies based on the association between *IL‐7R* polymorphisms and RA have rarely been reported. In our result, rs969129 and rs6451231 in *IL‐7R* gene firstly exhibited an increased risk of RA, suggesting that these *IL‐7R* variants were likely to be susceptible loci for RA in the Han Chinese population.

Although this study had sufficient statistical power, some potential limitations should be considered when decipher the results. First, the sample size of our study was relatively small when compared with previous GWAS studies. Second, our subjects were all Han Chinese people, so the results cannot be extrapolated to other people. Despite the limitations mentioned above, our present results provided scientific evidence of *IL‐7R* gene with RA in the future studies.

In a conclusion, there is a great desire for more case--control to find the genetic basis of RA. Fortunately, our study enriched this field. This study demonstrated that rs969129 and rs6451231 in *IL‐7R* gene were associated with an increased risk of RA, which has not previously been reported. Combined with the previous studies, we believe that the *IL‐7R* gene may be a new insight into the treatment of RA. Larger well‐designed epidemiological studies with more diverse populations and functional evaluations should be conducted.
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